查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球 PEG 化蛋白质市场
市场调查报告书
商品编码
1311906

2023-2030 年全球 PEG 化蛋白质市场

Global PEGylated Proteins Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

在预测期内，全球 PEG 化蛋白质市场预计将以 1.8% 的可观复合年增长率增长。癌症、肾病和类风湿性关节炎等慢性疾病的发病率不断上升，催生了对这些疾病治疗方案的需求，进而推动了全球 PEG 化蛋白质市场的增长。根据美国癌症协会 2022 年的数据，估计 2022 年美国将新增 1,908,030 例癌症病例。此外，根据同一资料来源，在所有癌症中，消化系统癌症占 343,040 例，乳腺癌预计将占 290,560 例新发癌症病例，其次是呼吸系统癌症，2022 年将有 254,850 例新发病例。此外，根据联合国艾滋病规划署发布的《2022 年全球艾滋病毒和艾滋病统计数据》，2021 年全球有 3840 万人感染艾滋病毒。因此，随着全球癌症、艾滋病、肺结核等慢性病和传染病的负担日益加重，对开发药物的需求预计也将增加，这将促进蛋白质的研究，从而推动 PEG 化蛋白质市场的发展。

生物技术和制药公司在 PEG 化蛋白质治疗领域的持续研发推动了全球 PEG 化蛋白质市场的发展。例如，2022 年 11 月，Nektar Therapeutics 在 2022 年癌症免疫疗法协会（SITC）年会上公布了 NKTR-288 的首个临床前数据。NKTR-288 是一种新型聚乙二醇（PEG） - γ 干扰素（IFN-γ）共轭物，旨在改变 IFN-γ 与其底物的结合，优化 IFN-γ 信号传导的持续时间。IFN-γ 是一种细胞因子，可诱导细胞抗原呈递，增强肿瘤抗原特异性细胞毒性 T 细胞反应，可应用于多个治疗领域，包括肿瘤学和传染病。

目 录

第 1 章：报告摘要

  • 行业现状分析与增长潜力展望
  • 研究方法和工具
  • 市场细分
    • 按细分市场
    • 按地区

第 2 章：市场概述与洞察

  • 报告范围
  • 分析师洞察与当前市场趋势
    • 主要结论
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Abcam Plc
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Laysan Bio, Inc.
    • 公司概况
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Thermo Fisher Scientific Inc.
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • 关键战略分析

第 4 章：市场细分

  • 按产品/服务分類的全球 PEG 化蛋白质市场
    • 耗材
    • 服务
  • 按最终用户分類的全球 PEG 化蛋白质市场
    • 制药和生物技术公司
    • 合同研究组织
    • 学术研究机构
  • 按应用分類的全球 PEG 化蛋白质市场
    • 癌症
    • 自身免疫性疾病
    • 肝炎
    • 多发性硬化症
    • 血友病
    • 胃肠道疾病
    • 其他疾病

第 5 章：地区分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Abcam plc
  • Aurigene Pharmaceutical Services Ltd.
  • Celares GmbH
  • Creative PEGworks
  • Enzon Pharmaceuticals, Inc.
  • Laysan Bio, Inc.
  • Merck KGaA
  • NOF America Corp.
  • Profacgen
  • Thermo Fisher Scientific, Inc.
Product Code: OMR2027513

Title: Global PEGylated Proteins Market Size, Share & Trends Analysis Report Market by Products/ Services (Consumables and Services), by End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutes), and by Application (Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders, and Others) Forecast Period (2023-2030).

The global PEGylated proteins market is anticipated to grow at a considerable CAGR of 1.8% during the forecast period. The increasing prevalence of chronic disorders such as cancer, kidney diseases, and rheumatoid arthritis has created demand for their treatment options; which in turn driving the growth of the global PEGylated proteins market. According to the data from the American Cancer Society 2022, an estimated 1,908,030 new cancer cases were diagnosed in the US in 2022. Moreover, as per the same source, among all cancers, digestive system cancer accounts for 343,040 cases, breast cancer is expected to account for 290,560 new cancer cases, followed by respiratory system cancer, with 254,850 new cases in 2022. Additionally, as per the Global HIV and AIDS Statistics, 2022 fact sheet by UNAIDS, 38.4 million people globally were living with HIV in 2021. Thus, with the growing burden of chronic and infectious diseases such as cancer, HIV, tuberculosis, and others globally, the demand for developing medicine is also expected to increase, this will promote the research on protein, thus driving the PEGylated protein market.

The on-going R&D in the field of PEGylated proteins therapeutics by biotechnology and pharmaceutical companies' has driven the global PEGylated proteins market. For instance, in November 2022, Nektar Therapeutics presented 1st preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. NKTR-288 is a novel polyethylene glycol (PEG)-the conjugate of interferon-gamma (IFN-γ); it is designed to modify the binding of IFN-γ to its substrates and optimize the duration of IFN-γ signaling. IFN-γ is a cytokine that induces cellular antigen presentation and enhances tumor antigen-specific cytotoxic T-cell response and may have applications in several therapeutic areas, including oncology and infectious diseases.

Further in March 2022, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million (USD 5.58 million) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourneyBiologics S.A. In addition, there is rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving the efficacy. However, the high drug failure rates and drug recalls are the major factors that may restrain the growth of the global PEGylated proteins market.

Segmental Outlook

The global PEGylated proteins market is segmented based on product/ services, end-user, and application. Based on product/services, the market is bifurcated into consumables and services. Based on end-user, the market is sub-segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Based on application, the market is sub-segmented into cancer, autoimmune diseases, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorders, other.

Consumables Sub-Segment to Hold a Considerable Share of the Global PEGylated Proteins Market

Among the product/ services, the consumables sub-segment is expected to hold a considerable share of the market. The consumables sub-segment is further bifurcated into PEGlyation reagents and PEGylation kits. The never-ending research activities, product developments, and the need to formulate better drugs as well as drug-delivery mechanisms contribute to continuous consumption of PEGylating consumables, such as kits and reagents, and thus result in high revenue generation. Moreover, the presence of major players with numerous product offerings also drives segment growth.

The advantages and developments in PEGylation technology along with the increasing demand for PEGylated products have caused a huge adoption of consumables. The versatile application of PEG in research and drug development programs has bolstered its usage. Furthermore, various custom PEG conjugation services & product-providing companies are continuously employing consumables for delivering the intended products. The fast depletion of consumables due to an upswing in demand for PEGylated proteins along with the presence of multiple product providers will contribute to revenue generation in the years to come.

Regional outlooks

The global PEGylated proteins market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, the Asia-Pacific region is anticipated to exhibit a healthy growth during forecast period.

North America to Hold a Major Share in the Global PEGylated Proteins Market

The presence of key players and availability of well established healthcare infrastructure are some of the key factors contributing to the high share of the regional market. According to the estimates of the American Cancer Society, in 2022, it was expected that 79,000 new instances of kidney cancer are likely to be diagnosed in the US in 2022, including 50,290 cases in males and 28,710 cases in women. The top 10 malignancies for both men and women include kidney cancer. Men have about a 1 in 46-lifetime risk of having kidney cancer (2.02%). For women, the lifetime risk is approximately 1 in 80. (1.03%). Thus, the growing prevalence of chronic diseases in the region is likely to propel the growth of the market.

Furthermore, the cohesive government initiatives and an increase in the number of research partnerships are some of the factors anticipated to drive market growth. For instance, in February 2021, Nautilus merged with Arya III, a special purpose acquisition company (SPAC), with an initial investment of $350 million to ramp up work developing its protein analysis technology for drug discovery and diagnostic applications.

Market Players Outlook

The major companies serving the global PEGylated proteins market include: Thermo Fisher Scientific, Inc., Abcam plc, Enzon Pharmaceuticals, Inc., Merck KGaA, and Celares GmbH among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including collaborations, and new product launches, to stay competitive in the market. For instance, In July 2022, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a favorable opinion, recommending the approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and AIDS-related Kaposi's sarcoma.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global PEGylated proteins market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abcam Plc
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Laysan Bio, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global PEGylated Proteins Market by Products/Services
    • 4.1.1. Consumables
    • 4.1.2. Services
  • 4.2. Global PEGylated Proteins Market by End-User
    • 4.2.1. Pharmaceutical & Biotechnology Companies
    • 4.2.2. Contract Research Organizations
    • 4.2.3. Academic & Research Institutes
  • 4.3. Global PEGylated Proteins Market by Application
    • 4.3.1. Cancer
    • 4.3.2. Autoimmune Diseases
    • 4.3.3. Hepatitis
    • 4.3.4. Multiple Sclerosis
    • 4.3.5. Hemophilia
    • 4.3.6. Gastrointestinal Disorders
    • 4.3.7. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abcam plc
  • 6.2. Aurigene Pharmaceutical Services Ltd.
  • 6.3. Celares GmbH
  • 6.4. Creative PEGworks
  • 6.5. Enzon Pharmaceuticals, Inc.
  • 6.6. Laysan Bio, Inc.
  • 6.7. Merck KGaA
  • 6.8. NOF America Corp.
  • 6.9. Profacgen
  • 6.10. Thermo Fisher Scientific, Inc.

LIST OF TABLES

  • 1. GLOBAL PEGYLATED PROTEINS MARKET BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 2. GLOBAL PEGYLATED PROTEINS CONSUMABLES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PEGYLATED PROTEINS SERVICES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PEGYLATED PROTEINS MARKET BY END-USER, 2022-2030 ($ MILLION)
  • 5. GLOBAL PEGYLATED PROTEINS FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL PEGYLATED PROTEINS FOR CONTRACT RESEARCH ORGANIZATIONS MARKET BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL PEGYLATED PROTEINS FOR ACADEMIC & RESEARCH INSTITUTES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL PEGYLATED PROTEINS MARKET BY APPLICATION, 2022-2030 ($ MILLION)
  • 9. GLOBAL PEGYLATED PROTEINS FOR CANCER TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 10. GLOBAL PEGYLATED PROTEINS FOR AUTOIMMUNE DISEASES TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 11. GLOBAL PEGYLATED PROTEINS FOR HEPATITIS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 12. GLOBAL PEGYLATED PROTEINS FOR MULTIPLE SCLEROSIS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 13. GLOBAL PEGYLATED PROTEINS FOR HEMOPHILIA TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 14. GLOBAL PEGYLATED PROTEINS FOR GASTROINTESTINAL DISORDERS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 15. GLOBAL PEGYLATED PROTEINS FOR OTHER DISEASE TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 16. GLOBAL PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 22. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 23. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 24. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY PRODUCTS/SERVICES, 2022 VS 2030 (%)
  • 2. GLOBAL PEGYLATED PROTEINS CONSUMABLES MARKET BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PEGYLATED PROTEINS SERVICES MARKET BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 5. GLOBAL PEGYLATED PROTEINS FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL PEGYLATED PROTEINS FOR CONTRACT RESEARCH ORGANIZATIONS MARKET BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL PEGYLATED PROTEINS BASED ACADEMIC & RESEARCH INSTITUTES MARKET BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 9. GLOBAL PEGYLATED PROTEINS FOR CANCER MARKET BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PEGYLATED PROTEINS FOR AUTOIMMUNE DISEASES MARKET BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL PEGYLATED PROTEINS FOR HEPATITIS MARKET BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL PEGYLATED PROTEINS FOR MULTIPLE SCLEROSIS MARKET BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL PEGYLATED PROTEINS FOR HEMOPHILIA MARKET BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL PEGYLATED PROTEINS FOR GASTROINTESTINAL DISORDERS MARKET BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL PEGYLATED PROTEINS FOR OTHER MARKET BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. US PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CANADA MARKET PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. UK PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. FRANCE PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF EUROPE PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. INDIA PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. CHINA PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. JAPAN PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OFASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF WORLD PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)